Results 51 to 60 of about 1,181 (123)

Recent Investigations on Pathogenesis, Biomarkers, Epigenetics, and Emerging Therapeutic Strategies to Modulate Multiple Signaling Pathways in Diabetic Retinopathy

Journal of Ophthalmology, Volume 2026, Issue 1, 2026.
Background Diabetic retinopathy (DR) is a progressive microvascular complication related to diabetes mellitus and remains a profound cause of vision impairment and blindness globally. In addition to its ocular manifestations, DR is increasingly recognized as a main risk factor for systemic diseases, including cardiovascular and neurodegenerative ...
Zixuan Huang, Jing Wei, Dayong Yang, Kofi Asiedu   +3 more
wiley   +1 more source

Review of Retinopathy of Prematurity Management in the Anti‐VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI‐Assisted Future

Clinical &Experimental Ophthalmology, Volume 53, Issue 9, Page 1202-1217, December 2025.
ABSTRACT Retinopathy of prematurity (ROP) remains a major cause of preventable blindness in premature infants worldwide, with increasing incidence due to advancements in neonatal care. Management of ROP has been revolutionised by anti‐vascular endothelial growth factor (anti‐VEGF) treatments.
Kyle V. Marra, Jimmy S. Chen, Eric Nudleman, Shira L. Robbins   +3 more
wiley   +1 more source

Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis

Acta Ophthalmologica, Volume 103, Issue 7, Page 741-763, November 2025.
Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler, Andreas Arnold‐Vangsted, Marianne G. Schou, Rodrigo Anguita, Jakob Bjerager, Enrico Borrelli, Lasse J. Cehofski, Lorenzo Ferro Desideri, Elon H. C. van Dijk, Carsten Faber, Jakob Grauslund, Javad N. Hajari, Josef Huemer, Oliver N. Klefter, Marie Krogh Nielsen, M. Cem Sabaner, Miklos Schneider, Yousif Subhi   +17 more
wiley   +1 more source

Intraocular Pharmacokinetics and Safety of Subretinal Injection Compared with Intravitreal Application of Conbercept in Vitrectomized Rabbit Eyes

Journal of Ophthalmology, 2020
Purpose. To evaluate the ocular pharmacokinetic properties of subretinal conbercept injection in vitrectomized rabbit eyes and to compare them with those by intravitreal injection. Methods.
Teng-teng Yao, Xiao-liang Jin, Yuan Yang, Yi-xiao Wang, Ya-li Zhou, Fang-lin He, Zhao-yang Wang   +6 more
doaj   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, Volume 1, Issue 2, Page 151-169, September 2025.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity

European Journal of Medical Research
Background To evaluate the effect and factors associated with the reactivation of retinopathy of prematurity (ROP) after intravitreal conbercept or aflibercept.
Chunling Huang, Weikang Zou, Wenbei Ma, Jiali Li, Yichen Bai, Rong Wu, Qiqi Li, Qi Fang, Wenna Chen, Xiaohe Lu, Songfu Feng   +10 more
doaj   +1 more source

Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy

iMetaOmics, Volume 2, Issue 2, June 2025.
This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang   +7 more
wiley   +1 more source

Natural products targeting tumour angiogenesis

British Journal of Pharmacology, Volume 182, Issue 10, Page 2094-2136, May 2025.
Abstract Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumour ...
Xiaohua Lu, Lara Johanna Friedrich, Thomas Efferth   +2 more
wiley   +1 more source

Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization

BMC Ophthalmology
Background To determine the efficacy and safety of intravitreally injected conbercept, a vascular endothelial growth factor receptor fusion protein, for the treatment of idiopathic choroidal neovascularization (ICNV).
Gaixia Zhai, Yuanzhen Su, Shaopeng Wang, Hui Lu, Na Liu   +4 more
doaj   +1 more source

Effect of Conbercept Treatment on Macular Edema and Microvascular Structure in Eyes with Retinal Vein Occlusions

International Journal of General Medicine, 2022
Xiaoxia Ding, Yu Wang, Bo Zou, Dongxiao Zang, Yi Hao Department of Ophthalmology, Fushun Eye Hospital, Fushun, Liaoning, People’s Republic of ChinaCorrespondence: Xiaoxia Ding, Fushun Eye Hospital, No.
Ding X, Wang Y, Zou B, Zang D, Hao Y
doaj